Navigation Links
Genedata Expressionist Enhances Automated Characterization of Biopharmaceuticals by Mass Spectrometry
Date:1/28/2020

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the release of Genedata Expressionist® 13.5 at the 2020 WCBP Symposium. This release reinforces Genedata’s focus on supporting the implementation of Multi-Attribute Methods (MAM) for characterizing and monitoring the quality of biopharmaceuticals throughout their development and manufacturing. By further enhancing its best-in-class characterization capabilities and expanding its comprehensive overview of analytical results with novel, advanced visualizations, Genedata Expressionist 13.5 facilitates the automatic identification and definition of critical quality attributes (CQAs) and enables MAM implementations driven by the principle of quality by design.

Developed in close collaboration with partners across the biopharmaceutical industry, Genedata Expressionist provides unique workflow solutions for specific customer requirements. Out-of-the box data processing and analysis activities are configured to fully automate complex mass spectrometry-based workflows enabling users to effortlessly scale up their experimental throughput while improving the quality and consistency of results.

The new release includes the following highlights:

  • New peptide mapping functionalities that enable searches for unexpected “wildcard” modifications and facilitate thorough review of results, accelerating analyses and providing best-in-class molecular characterization—important for next-generation MAM implementations.
  • Novel intact mass analysis providing automated deconvolution over broad mass ranges up to 1 MDa with artefact suppression and a selection of full-range or zoomed views—improving the resolution and relative quantitation of coeluting species in analysis of intact proteins or subunits.

This release also sees Genedata welcoming SCIEX as its latest Ready-to-Run partner, enabling seamless integration with the newest SCIEX mass spectrometers and data formats—such as wiff and wiff2—and providing fast, high-performance processing of large volumes of raw data. The program provides innovative technology leaders like Genedata and SCIEX with a simple way to help joint customers automate complex data workflows, and eliminates the time and costs associated with integration services and projects, ultimately reducing customers’ total cost of ownership.

"The latest release of Genedata Expressionist—an important component of our Genedata Biopharma Platform—reinforces our continued commitment to support rapidly evolving needs of the biopharmaceutical industry, such as support of MAM. Genedata Expressionist enables our customers to efficiently scale up their internal data processing workflows, while at the same time improving result quality," commented Othmar Pfannes, Ph.D., CEO of Genedata. "Furthermore, we remain committed to partnering with leading technology providers such as SCIEX to offer our joint customers new solutions not only to accelerate discovery, development, and commercialization of novel biopharmaceuticals, but also to reduce costs by streamlining and automating complex analytical processes."

About Genedata
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI in their R&D, spanning early discovery all the way to the clinic. Founded in 1997, Genedata is headquartered in Switzerland with additional offices in Germany, Japan, Singapore, the UK, and the US.
http://www.genedata.com
LinkedIn | Twitter | YouTube
________________________________________
Contact
Miles Fisher-Pollard
Genedata
Public Relations
Phone: +41 61 511 85 61
pr@genedata.com

Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Read the full story at https://www.prweb.com/releases/genedata_expressionist_enhances_automated_characterization_of_biopharmaceuticals_by_mass_spectrometry/prweb16866951.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology technology :

1. Immatics Implements Genedata Biologics® into Proprietary T-Cell Receptor Discovery and Engineering XCEPTOR® Platform
2. Genedata Bioprocess Offers Out-of-the-Box Integration with ambr Bioreactors
3. Genedata Screener Strengthens Collaborative Research at Axxam
4. Genedata Trailblazing Automation of Image Analysis for High Content Screening with Early Access to Deep Learning
5. Merck uses Genedata Biologics to Scale-Up Bispecific Antibody Discovery Programs
6. Genedata Expands Partnership with AB Enzymes
7. Genedata Announces New Solution for Efficient Analysis of High-Throughput Automated Patch Clamp Experiments
8. Genedata Expressionist 11.0 Released at ASMS 2017
9. Genedata Celebrates 20 Years of Bioinformatics Innovations at Bio-IT World
10. Leading Pharma and Research Organizations to Attend Genedata Screener Global User Group Meetings
11. Genedata Expands Into United Kingdom
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/10/2020)... WORTH, Texas (PRWEB) , ... March 10, 2020 , ... ... manufacturing facility on 13 acres in Cleburne, Texas to be used as a biopharmaceutical ... as its global headquarters and sales offices as well as its production and development ...
(Date:3/4/2020)... ... March 04, 2020 , ... This month, Cognosante will make ... The company will showcase both expanded and emerging offerings that align with the HIMSS ... is designed to be comprehensive, timely, and engaging. From Interoperability and HIE ...
(Date:3/3/2020)... ... March 03, 2020 , ... Ideal ... the latest breast implant technology at the IMCAS Innovation Shark Tank 2020 in ... the dermatology, plastic surgery, and aesthetic science industries that promise to revolutionize medical ...
(Date:2/28/2020)... ... February 26, 2020 , ... ... a high-speed camera with a dedicated controller, thus simplifying setup, streamlining integration, and ... HS7 is the first of Fastec Imaging’s new HS Series cameras to be ...
Breaking Biology Technology:
(Date:3/5/2020)... , ... March 05, 2020 , ... Patients in need ... dental implants from Dr. Nickelice Brand of Dental Implants of Ocala. Same-day dental ... get an entirely new smile in just one day. This treatment utilizes advanced technology ...
(Date:3/4/2020)... , ... March 04, 2020 , ... ... products and services, announced it has been nominated as a finalist in the ... Awards. This nomination comes as VGXI expedites manufacturing of a DNA vaccine against ...
(Date:3/2/2020)... ... ... Philadelphia IP law firm Panitch Schwarze Belisario & Nadel LLP is pleased ... Partner, and Stephany G. Small, Ph.D., has joined the firm as a patent agent. ... in the firm’s biotechnology and life science practice group. He has significant experience with ...
Breaking Biology News(10 mins):